cept Therapeutics rporated(CORT)

Search documents
cept Therapeutics rporated(CORT) - 2019 Q2 - Earnings Call Transcript
2019-08-02 07:37
Corcept Therapeutics Inc. (NASDAQ:CORT) Q2 2019 Earnings Conference Call August 1, 2019 5:00 PM ET Company Participants Charlie Robb - CFO Joseph Belanoff - CEO Andreas Grauer - Chief Medical Officer Conference Call Participants Tazeen Ahmad - Bank of America Matt Kaplan - Ladenburg Thalmann Neil Carnahan - Stifel Operator Good day, and welcome to the Corcept Therapeutics Conference Call. Today's conference is being recorded. [Operator Instructions] At this time, I would like to turn the conference over to ...
cept Therapeutics rporated(CORT) - 2019 Q2 - Quarterly Report
2019-08-01 21:21
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q _______________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 _____________________ ...
cept Therapeutics rporated(CORT) - 2019 Q1 - Earnings Call Transcript
2019-05-10 02:56
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2019 Results Earnings Conference Call May 9, 2019 5:00 PM ET Company Participants Charlie Robb - Chief Financial Officer Joseph Belanoff - Chief Executive Officer Andreas Grauer - Chief Medical Officer Conference Call Participants Matt Kaplan - Ladenburg Thalmann Neil Carnahan - Stifel Operator Good day everyone and welcome to the Corcept Therapeutics Conference Call. Today's call is being recorded. [Operator Instructions]. At this time, I would like to tur ...
cept Therapeutics rporated(CORT) - 2019 Q1 - Quarterly Report
2019-05-09 21:13
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q _______________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 ____________________ ...
cept Therapeutics rporated(CORT) - 2018 Q4 - Earnings Call Transcript
2019-02-26 01:27
Corcept Therapeutics Inc. (NASDAQ:CORT) Q4 2018 Earnings Conference Call February 25, 2019 5:00 PM ET Company Participants Charlie Robb - CFO Dr. Joseph Belanoff - CEO Conference Call Participants Adam Walsh - Stifel David Buck - B. Riley FBR Peter Stapor - Cantor Fitzgerald Matt Kaplan - Ladenburg Thalmann Alan Leong - BioWatch News Operator Good day everyone and welcome to the Corcept Therapeutics Conference Call. Today's call is being recorded. [Operator Instructions] At this time, I would like to turn t ...
cept Therapeutics rporated(CORT) - 2018 Q4 - Annual Report
2019-02-25 23:19
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEUTICS INCORPORATED (Exact Name of Corporation as Specified in Its Charter) Delaware 77-0487658 (State or other jurisdictio ...